- 関
- NPY receptor
WordNet
- a cellular structure that is postulated to exist in order to mediate between a chemical agent that acts on nervous tissue and the physiological response
- the 25th letter of the Roman alphabet (同)y, wye
PrepTutorEJDIC
- =sense organ / 受信装置
- yttriumの化学記号
- y-axis
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/08/28 02:31:34」(JST)
[Wiki en表示]
| neuropeptide Y receptor Y1 |
| Identifiers |
| Symbol |
NPY1R |
| Alt. symbols |
NPYR |
| Entrez |
4886 |
| HUGO |
7956 |
| OMIM |
162641 |
| RefSeq |
NM_000909 |
| UniProt |
P25929 |
| Other data |
| Locus |
Chr. 4 q31.3-q32 |
| neuropeptide Y receptor Y2 |
| Identifiers |
| Symbol |
NPY2R |
| Entrez |
4887 |
| HUGO |
7957 |
| OMIM |
162642 |
| RefSeq |
NM_000910 |
| UniProt |
P49146 |
| Other data |
| Locus |
Chr. 4 q31 |
| pancreatic polypeptide receptor 1 |
| Identifiers |
| Symbol |
PPYR1 |
| Alt. symbols |
NPY4R, Y4, PP1 |
| Entrez |
5540 |
| HUGO |
9329 |
| OMIM |
601790 |
| RefSeq |
NM_005972 |
| UniProt |
P50391 |
| Other data |
| Locus |
Chr. 10 q11.2 |
| neuropeptide Y receptor Y5 |
| Identifiers |
| Symbol |
NPY5R |
| Entrez |
4889 |
| HUGO |
7958 |
| OMIM |
602001 |
| RefSeq |
NM_006174 |
| UniProt |
Q15761 |
| Other data |
| Locus |
Chr. 4 q31-q32 |
Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]
Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.
Contents
- 1 Types
- 2 Antagonists
- 3 References
- 4 External links
Types
There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[9][10][11]
- Y1 - NPY1R
- Y2 - NPY2R
- Y4 - PPYR1
- Y5 - NPY5R
Antagonists
- BIBP-3226
- Lu AA-33810
- BIIE-0246
- UR-AK49
References
- ^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.
- ^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.
- ^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.
- ^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774.
- ^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213.
- ^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780.
- ^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
- ^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.
- ^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
- ^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781.
- ^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782.
External links
- "Neuropeptide Y Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
- Neuropeptide Y Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)
|
Cell surface receptor: G protein-coupled receptors
|
|
|
|
|
|
Class B: Secretin like
|
|
| Orphan |
- GPR (56
- 64
- 97
- 98
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 123
- 124
- 125
- 126
- 128
- 133
- 143
- 144
- 155
- 157)
|
|
| Other |
- Brain-specific angiogenesis inhibitor (1
- 2
- 3)
- Cadherin (1
- 2
- 3)
- Calcitonin
- CALCRL
- CD97
- Corticotropin-releasing hormone (1
- 2)
- EMR (1
- 2
- 3)
- Glucagon (GR
- GIPR
- GLP1R
- GLP2R)
- Growth hormone releasing hormone
- PACAPR1
- GPR
- Latrophilin (1
- 2
- 3
- ELTD1)
- Methuselah-like proteins
- Parathyroid hormone (1
- 2)
- Secretin
- Vasoactive intestinal peptide (1
- 2)
|
|
|
|
|
Class C: Metabotropic glutamate / pheromone
|
|
| Taste |
- TAS1R (1
- 2
- 3)
- TAS2R (1
- 3
- 4
- 5
- 7
- 8
- 9
- 10
- 13
- 14
- 16
- 19
- 20
- 30
- 31
- 38
- 39
- 40
- 41
- 42
- 43
- 45
- 46
- 50
- 60)
|
|
| Other |
- Calcium-sensing receptor
- GABA B (1
- 2)
- Glutamate receptor (Metabotropic glutamate (1
- 2
- 3
- 4
- 5
- 6
- 7
- 8))
- GPRC6A
- GPR (156
- 158
- 179)
- RAIG (1
- 2
- 3
- 4)
|
|
|
|
|
Class F: Frizzled / Smoothened
|
|
| Frizzled |
- Frizzled (1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10)
|
|
| Smoothened |
|
|
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
Neuropeptide receptors
|
|
| G protein-coupled receptor |
| Hormone receptors |
| Hypothalamic |
- CRH
- FSH
- LHRH
- TRH
- Somatostatin
|
|
| Pituitary |
- Vasopressin
- Oxytocin
- LHCG
- TSH
|
|
| Other |
- Atrial natriuretic factor
- Calcitonin
- Cholecystokinin
- VIP
|
|
|
| Opioid receptors |
- Delta
- Kappa
- Mu
- Nociceptin
|
|
| Other neuropeptide receptors |
- Angiotensin
- Bradykinin
- Tachykinin
- Calcitonin gene-related peptide
- Galanin
- GPCR neuropeptide
- Neurotensin
|
|
|
| Type I cytokine receptor |
|
|
| Enzyme-linked receptor |
- Atrial natriuretic factor
|
|
| Other |
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
Neuropeptidergics
|
|
| Cholecystokinin |
|
CCKA
|
- Agonists: Cholecystokinin
- CCK-4
Antagonists: Amiglumide
- Asperlicin
- Devazepide
- Dexloxiglumide
- Lintitript
- Lorglumide
- Loxiglumide
- Pranazepide
- Proglumide
- Tarazepide
- Tomoglumide
|
|
|
CCKB
|
- Agonists: Cholecystokinin
- CCK-4
- Gastrin
Antagonists: CI-988 (PD-134,308)
- Itriglumide
- L-365,360
- Netazepide
- Proglumide
- Spiroglumide
|
|
|
| CRH |
|
CRF1
|
- Agonists: Corticorelin
- Corticotropin releasing hormone
- Sauvagine
- Stressin I
- Urocortin
Antagonists: Antalarmin
- Astressin-B
- CP-154,526
- LWH-234
- NBI-27914
- Pexacerfont
- R-121,919
|
|
|
CRF2
|
- Agonists: Corticorelin
- Corticotropin releasing hormone
- Sauvagine
- Urocortin
Antagonists: Astressin-B
|
|
|
| Galanin |
|
GAL1
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
|
GAL2
|
- Agonists: Galanin
- Galanin-like peptide
- Galmic
- Galnon
|
|
|
GAL3
|
- Agonists: Galanin
- Galmic
- Galnon
|
|
|
| MCH |
|
MCH1
|
- Agonists: Melanin concentrating hormone
Antagonists: ATC-0175
- GW-803,430
- NGD-4715
- SNAP-7941
- SNAP-94847
|
|
|
MCH2
|
- Agonists: Melanin concentrating hormone
|
|
|
| Melanocortin |
|
MC1
|
- Agonists: alpha-MSH
- Afamelanotide
- BMS-470,539
- Bremelanotide
- Melanotan II
Antagonists: Agouti signalling peptide
|
|
|
MC2
|
- Agonists: ACTH
- Cosyntropin
- Tetracosactide
|
|
|
MC3
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
|
|
|
MC4
|
- Agonists: alpha-MSH
- Bremelanotide
- Melanotan II
- PF-00446687
- THIQ
Antagonists: Agouti-related peptide
|
|
|
MC5
|
- Agonists: alpha-MSH
- Melanotan II
|
|
|
Unsorted
|
- Agonists: Alsactide
- Codactide
- Giractide
- Norleusactide
- Seractide
- Tosactide
- Tricosactide
- Tridecactide
|
|
|
| Neuropeptide S |
- Agonists: Neuropeptide S
Antagonists: SHA-68
|
|
| Neuropeptide Y |
|
Y1
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIBP-3226
|
|
|
Y2
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: BIIE-0246
|
|
|
Y4
|
- Agonists: Neuropeptide Y
- Pancreatic polypeptide
- Peptide YY
Antagonists: UR-AK49
|
|
|
Y5
|
- Agonists: Neuropeptide Y
- Peptide YY
Antagonists: Lu AA-33810
|
|
|
| Neurotensin |
|
NTS1
|
- Agonists: Neurotensin
- Neuromedin N
Antagonists: Meclinertant
- SR-142,948
|
|
|
NTS2
|
- Agonists: Neurotensin
Antagonists: Levocabastine
- SR-142,948
|
|
|
| Opioid |
See Template:Opioidergics instead.
|
|
| Orexin |
|
OX1
|
- Agonists: Orexin-A
Antagonists: Almorexant
- Filorexant
- SB-334,867
- SB-408,124
- SB-649,868
- Suvorexant
|
|
|
OX2
|
- Agonists: Orexin-A
Antagonists: Almorexant
- Filorexant
- SB-649,868
- Suvorexant
- TCS-OX2-29
|
|
|
| Oxytocin |
- Agonists: Aspartocin
- Carbetocin
- Cargutocin
- Demoxytocin
- Nacartocin
- Oxytocin
- TC OT 39
- TGOT
- Vasotocin (argiprestocin)
- WAY-267,464
Antagonists: Atosiban
- Barusiban
- Epelsiban
- L-368,899
- L-371,257
- L-372,662
- Retosiban
- SSR-126,768
- Tocinoic acid
- WAY-162,720
|
|
| Tachykinin |
|
NK1
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Burapitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- Figopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium besilate
- Orvepitant
- Rolapitant
- RP-67,580
- SDZ NKT 343
- Serlopitant
- Telmapitant
- Vestipitant
- Vofopitant
|
|
|
NK2
|
- Agonists: Neurokinin A
Antagonists: GR-159,897
- Ibodutant
- Nepadutant
- Saredutant
|
|
|
NK3
|
- Agonists: Neurokinin B
Antagonists: Osanetant
- Talnetant
|
|
|
| Vasopressin |
|
V1A
|
- Agonists: Felypressin
- Lypressin
- Ornipressin
- Selepressin
- Terlipressin
- Vasopressin (argipressin)
- Vasotocin (argiprestocin)
Antagonists: Atosiban
- Conivaptan
- Demeclocycline
- PF-184563
- Relcovaptan
- RG7314
- TC OT 39
- WAY-267,464
|
|
|
V1B
|
- Agonists: Desmopressin
- Felypressin
- Lypressin
- Ornipressin
- Terlipressin
- Vasopressin (argipressin)
- Vasotocin (argiprestocin)
Antagonists: Demeclocycline
- Nelivaptan
|
|
|
V2
|
- Agonists: Desmopressin
- Felypressin
- Lypressin
- Ornipressin
- TC OT 39
- Terlipressin
- Vasopressin (argipressin)
- Vasotocin (argiprestocin)
Antagonists: Conivaptan
- Demeclocycline
- Lixivaptan
- Mozavaptan
- Satavaptan
- Tolvaptan
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Altered expression of neuropeptide Y receptors caused by focal cortical dysplasia in human intractable epilepsy.
- Li L1,2,3, Deng J1,2,3, Liu C1, Luo H4, Guan Y1, Zhou J1, Qi X1, Li T2,3, Xu ZD3,4,5, Luan GM1,2,3.
- Oncotarget.Oncotarget.2016 Mar 2. doi: 10.18632/oncotarget.7855. [Epub ahead of print]
- Focal cortical dysplasia (FCD) is a common cause of pharmacologically-intractable epilepsy, however, the precise mechanisms underlying the epileptogenicity of FCD remains to be determined. Neuropeptide Y (NPY), an endogenous anticonvulsant in the central nervous system, plays an important role in th
- PMID 26943580
- Radiosynthesis and in Vivo Evaluation of Neuropeptide Y5 Receptor (NPY5R) PET Tracers.
- Kumar JS1,2, Walker M3, Packiarajan M3, Jubian V3, Prabhakaran J4, Chandrasena G3, Pratap M1, Parsey RV2, Mann JJ1,4.
- ACS chemical neuroscience.ACS Chem Neurosci.2016 Feb 22. [Epub ahead of print]
- Neuropeptide Y receptor type 5 (NPY5R) is a G-protein coupled receptor (GPCR) that belongs to the subfamily of neuropeptide receptors (NPYR) that mediate the action of endogenous neuropeptide Y (NPY). Animal models and preclinical studies indicate a role for NPY5R in the pathophysiology of depressio
- PMID 26886507
- Prawn Shell Chitosan Exhibits Anti-Obesogenic Potential through Alterations to Appetite, Affecting Feeding Behaviour and Satiety Signals In Vivo.
- Egan ÁM1, O'Doherty JV1, Vigors S1, Sweeney T2.
- PloS one.PLoS One.2016 Feb 22;11(2):e0149820. doi: 10.1371/journal.pone.0149820. eCollection 2016.
- The crustacean shells-derived polysaccharide chitosan has received much attention for its anti-obesity potential. Dietary supplementation of chitosan has been linked with reductions in feed intake, suggesting a potential link between chitosan and appetite control. Hence the objective of this experim
- PMID 26901760
Japanese Journal
- Relationship between the Production Traits and three Candidate Genes in the Prolactin's In/Del×In/Del Population of Silkie Fowl
- Rahman Mijanur,Matsuda Riho,Matsuda Tomoe [他]
- Journal of poultry science 51(2), 138-143, 2014-04
- NAID 40020045284
- Galanin-3 Receptor Antagonism by SNAP 37889 Reduces Motivation to Self-administer Alcohol and Attenuates Cue-Induced Reinstatement of Alcohol-Seeking in iP Rats
- Ash Belinda L.,Quach Tim,Williams Spencer J.,Lawrence Andrew J.,Djouma Elvan
- Journal of Pharmacological Sciences 125(2), 211-216, 2014
- … The neuropeptide galanin has a role in promoting alcohol consumption and general feeding behavior. … The galanin-3 receptor (GALR3) subtype is implicated in modulating the consumption of alcohol and has therefore been identified as a potential target for new pharmacotherapies to treat alcohol use disorders. …
- NAID 130004438626
- Regulation of neuropeptide Y Y1 receptor expression by bone morphogenetic protein 2 in C2C12 myoblasts
- Kurebayashi Naoko,Sato Mari,Fujisawa Toshiaki,Fukushima Kazuaki,Tamura Masato
- Biochemical and Biophysical Research Communications 439(4), 506-510, 2013-10-04
- … The neuropeptide Y (NPY) system is known as one of the major neural signaling pathways. … NPY, produced by peripheral tissues including osteoblasts, is known to bind to the Y1 receptor. … Recently, osteoblast-specific Y1 receptor knockout mice were developed and were found to have a high bone mass phenotype, indicating a role for the NPY-Y1 receptor axis as a regulator of bone homeostasis. …
- NAID 120005324568
Related Links
- Neuropeptide Y (NPY) is widely distributed in the human body and contributes to a vast number of physiological processes. Since its discovery, NPY has been implicated in metabolic regulation and, although interest in its role in ...
- Neuropeptide Y (NPY) acts as a neurotransmitter in the brain and in the autonomic nervous system. In the brain it is thought to have several functions, including increasing food intake and storage of energy as fat [PMID: 6549409, PMID: 16874931 ...
Related Pictures
★リンクテーブル★
[★]
- 関
- neuropeptide Y receptor
[★]
- 英
- neuropeptide Y receptor、NPY receptor
- 関
- ニューロペプチドYレセプター
[★]
- 英
- neuropeptide Y receptor、NPY receptor
- 関
- ニューロペプチドY受容体
[★]